On Monday, MaxCyte Inc (NASDAQ: MXCT) was -4.90% drop from the session before settling in for the closing price of $1.43. A 52-week range for MXCT has been $1.26 – $5.20.
Healthcare Sector giant saw their annual sales slid by -11.37% over the last five years. When this article was written, the company’s average yearly earnings per share was at 0.22%. With a float of $98.66 million, this company’s outstanding shares have now reached $106.64 million.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward MaxCyte Inc stocks. The insider ownership of MaxCyte Inc is 7.51%, while institutional ownership is 70.69%. The most recent insider transaction that took place on Jun 25 ’25, was worth 22,378. In this transaction Director of this company sold 10,684 shares at a rate of $2.09, taking the stock ownership to the 39,893 shares. Before that another transaction happened on Aug 13 ’25, when Company’s CHIEF FINANCIAL OFFICER bought 50,000 for $1.29, making the entire transaction worth $64,500. This insider now owns 161,811 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.1 earnings per share (EPS) during the time that was better than consensus figure (set at -0.12) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.94% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
You can see what MaxCyte Inc (MXCT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.27 in one year’s time.
